Related Experiment Video
Updated: Sep 11, 2026

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics
Published on: October 2, 2014
Commercial development considerations for biotechnology-derived therapeutics
1Department of Comparative Medicine, XOMA (US) LLC, Berkeley, CA 94710, USA.
Abstract:
Although it seems unlikely, it has only been 20 years since the US Food and Drug Administration (FDA) approved the first recombinant protein as a therapeutic modality. Unbelievably, an average of slightly more than two approvals per year of monoclonal antibodies (MAbs) and other human protein therapeutics has been achieved by this burgeoning industry 43 recombinant protein therapeutics in the two decades since 1982 (see Table 1), and the pace is increasing.
More Related Videos
Related Concept Videos
Synthetic Biology
Golden rice
Golden rice is a genetically modified...
Clinical Trials: Overview
Preclinical Development: Overview
Drug Products: Biologics, Biosimilars and Interchangeables
Microorganisms in Medicine and Therapeutics
Upstream Processing

